

MammaTyper® LRP Score Demonstrates Prognostic Value in Early Luminal Breast Cancer

Study published in Clinical Breast Cancer supports MammaTyper® LRP as a quantitative molecular tool for risk assessment and chemotherapy decision-making

BERLIN, GERMANY, September 11, 2026 /EINPresswire.com/ -- A new study published in Clinical



MammaTyper® has the potential to become a broadly accessible multigene expression profiling tool offering guidance on precision breast cancer treatment."

Professor Ling Xu of Peking University First Hospital

Breast Cancer provides clinical evidence supporting the prognostic value of the [MammaTyper®](#) LRP score in patients with early-stage luminal breast cancer. The study, led by Professor Ling Xu of Peking University First Hospital, demonstrates that LRP is an independent prognostic factor and may help identify patients with a low risk of distant recurrence who may have limited benefit from adjuvant chemotherapy.

Luminal breast cancer, generally characterized by estrogen receptor (ER) and/or progesterone receptor (PR) positivity and HER2 negativity, accounts for a substantial proportion

of breast cancer cases. Although endocrine therapy is a cornerstone of treatment, determining whether adjuvant chemotherapy is necessary can be challenging. Multigene expression assays can provide additional biological information beyond conventional clinicopathological factors and support more individualized treatment decisions.

Oncotype DX®, the established 21-gene assay, has been widely used internationally to support treatment decisions in early-stage hormone receptor-positive, HER2-negative breast cancer. However, access to the test remains limited in many parts of the world. MammaTyper® has previously demonstrated in direct comparative studies the ability to identify low-risk patients with Oncotype DX® Recurrence Score ≤ 25 . The newly published study provides additional evidence of the prognostic relevance of the MammaTyper® LRP score.

The retrospective study included 402 patients with early-stage luminal breast cancer treated at Peking University First Hospital between 2014 and 2018. Patients had T1–2, N0–1 disease, and the median follow-up exceeded seven years. The study reported:

- LRP score was an independent prognostic factor, with an adjusted hazard ratio (HR) of 0.37 in

multivariable analysis.

- Patients in the LRP low-risk group achieved a 9-year distant disease-free survival (DDFS) rate of 96.2%, compared with 87.0% in the LRP high-risk group.
- The difference between the two groups was statistically significant (HR=0.28; p=0.0021).
- Among patients classified as LRP low risk, 9-year DDFS was favorable and broadly comparable regardless of whether patients received adjuvant chemotherapy, suggesting that the LRP score may help identify patients with a favorable long-term prognosis.

Professor Ling Xu of Peking University First Hospital, the study's principal investigator, commented: "Assessing the prognosis of early luminal breast cancer solely on the basis of conventional clinicopathological characteristics has limitations and may contribute to overtreatment in some patients. Oncotype DX® and other genomic assays generally are costly and have limited accessibilities in many parts of the world. MammaTyper® has previously demonstrated the ability to identify low-risk population characterized by Oncotype DX® (RS≤25), and our study further validates its prognostic value. With its lower testing cost and local availability, MammaTyper® has the potential to become a broadly accessible multigene expression profiling tool offering guidance on precision breast cancer treatment."

About MammaTyper®

MammaTyper® is an innovative assay for the quantitative determination of the four key biomarkers used in the subtyping of breast cancer (Human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), progesterone receptor (PR) and Ki-67). Applying sensitive and quantitative RT-qPCR techniques, it is a quick, accurate, reliable, and reproducible solution that enables medical professionals to accurately tailor treatment plans for the best chance of success. MammaTyper® is the only assay of its type on the market that is backed by extensive data and research. Further information on MammaTyper® is available at <https://cercabiotech.com/product/mammatyper/>.

References

Ding M, et al., Clinical validation of the MammaTyper® LRP model for identification of low risk patients with early-stage ER+/HER2- breast cancer: from subtyping to chemotherapy de-escalation, Clinical Breast Cancer. Available online 24 August 2026

About [Cerca Biotech](#)

Cerca Biotech is a diagnostic company based in Germany focused on bringing novel and innovative diagnostic products to the oncology and women's health market. We strive to introduce the best tests to meet the unmet clinical needs at an affordable cost, with clinical accuracy and rapid results as our focus. Utilising a combination of experienced distributors and direct sales Cerca Biotech has a commercial reach from Germany through the Nordics and Eastern Europe to the Middle East, Africa, India and beyond. Our team comprises of highly experienced commercial, technical and clinical experts in the field of IVD, allowing rapid deployment of novel technologies with a "get it right first time" strategy. For more information, visit the company website at www.cercabiotech.com or contact info@cercabiotech.com

Richard Hughes

Cerca Biotech GmbH

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/941440639>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.